China Shineway(2877: HK): Beneficiary from Deregulation of Non-Essential Drug in Grassroots Level
471 Views24 Jul 2018 15:19
A year ago, I wrote about China Shineway Pharmaceutical Group Ltd. (2877 HK) that has a couple of low-cost drugs that sell in the second and third...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- China Shineway: Cash Is 85% of Market Cap, and New Dividend Policy Gives More Downside Support28 Oct 2021
- Best World: Buying Opportunity Due to Delayed Revenue Recognition17 May 2018
- The Only Company that May Benefit from Shijiazhuang Incident?22 Apr 2017
- Consun Pharma - FY16 Announced; Strong Growth and Increased Stake in Yulin30 Mar 2017
x